Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038632 | 0.92 | ALDH1A1 (0.61) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL4488519 | 0.92 | ALDH1A1 (0.66) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL656530 | 0.85 | ALDH1A1 (0.71) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL8298069 | 0.83 | ALDH1A1 (0.70) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL2717007 | 0.83 | TMEM97 (0.68) | ALDH1A1LMNASMN1; SMN2POLBKMT2A | |
| SCHEMBL9492603 | 0.83 | ALDH1A1 (0.76) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL6835143 | 0.83 | ALDH1A1 (0.71) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL5507075 | 0.82 | ALDH1A1 (0.70) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL7746602 | 0.82 | ALDH1A1 (0.68) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL11111589 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HPGDL3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| CN-1933839-A | Compounds and methods of use | AMGEN INC (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1664053-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050070554-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005021551-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-6858641-B2 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| CN-1509270-A | Indolinones substituted in the 6-position, process for their preparation and their use as kinase inhibitors | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-06-30 | — | — | CN | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
| EP-1379501-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092756-A1 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-15 | — | — | US | disclosed |
| WO-2002081445-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092756-A1 | Substituted indolinones | CDK1, CDK2, CDKL1 | ALDH1A1 1526/4885HPGD 1513/4885L3MBTL1 4747/4885 |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | ALDH1A1 370/4885HPGD 1495/4885L3MBTL1 4158/4885 |
| US-20050070554-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, PAICS | ALDH1A1 774/4885HPGD 607/4885L3MBTL1 4153/4885 |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | ALDH1A1 1144/4885HPGD 1188/4885L3MBTL1 1484/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | ALDH1A1 81/4885HPGD 150/4885L3MBTL1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.